Sanofi Long Term Debt Total vs Net Working Capital Analysis

SNY Stock

USD 49.01 0.45 0.91%

Sanofi ADR financial indicator trend analysis is much more than just breaking down Sanofi ADR prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Sanofi ADR is a good investment. Please check the relationship between Sanofi ADR Long Term Debt Total and its Net Working Capital accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

Long Term Debt Total vs Net Working Capital

Long Term Debt Total vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Sanofi ADR Long Term Debt Total account and Net Working Capital. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Sanofi ADR's Long Term Debt Total and Net Working Capital is -0.39. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Sanofi ADR, assuming nothing else is changed. The correlation between historical values of Sanofi ADR's Long Term Debt Total and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Sanofi ADR are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Long Term Debt Total i.e., Sanofi ADR's Long Term Debt Total and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.39

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Long Term Debt Total

Net Working Capital

Most indicators from Sanofi ADR's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Sanofi ADR current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.At this time, Sanofi ADR's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 203.7 M in 2024, despite the fact that Discontinued Operations is likely to grow to (110.3 M).

	2021	2022	2023	2024 (projected)
Gross Profit	26.9B	31.7B	26.5B	21.8B
Total Revenue	39.2B	45.4B	43.1B	31.0B

Gross Profit Total Revenue

Sanofi ADR fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Good Will	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets
Total Assets		0.88	0.05	0.92	0.99	0.97	0.66	0.78	0.78	0.99	-0.47	0.69	0.23	1.0	0.87	0.83	-0.61	0.91	0.82	-0.06	-0.34	0.98	0.42	0.9	0.59	0.27
Short Long Term Debt Total	0.88		-0.13	0.85	0.81	0.8	0.86	0.85	0.76	0.86	-0.56	0.7	0.1	0.88	0.6	0.62	-0.38	0.9	0.83	-0.3	-0.52	0.94	0.2	0.83	0.6	0.06
Other Current Liab	0.05	-0.13		0.17	0.08	-0.01	-0.08	-0.37	-0.13	0.07	0.81	-0.11	0.19	0.04	0.25	0.01	-0.09	-0.11	-0.44	0.09	0.14	0.0	0.91	-0.01	-0.12	0.81
Total Current Liabilities	0.92	0.85	0.17		0.92	0.85	0.6	0.74	0.81	0.89	-0.31	0.77	0.05	0.92	0.69	0.6	-0.37	0.74	0.67	-0.11	-0.54	0.91	0.46	0.92	0.57	0.26
Total Stockholder Equity	0.99	0.81	0.08	0.92		0.98	0.57	0.74	0.77	0.98	-0.43	0.69	0.21	0.99	0.89	0.84	-0.62	0.86	0.79	-0.01	-0.32	0.95	0.45	0.89	0.57	0.3
Property Plant And Equipment Net	0.97	0.8	-0.01	0.85	0.98		0.61	0.73	0.71	0.97	-0.51	0.61	0.27	0.97	0.91	0.89	-0.66	0.9	0.83	-0.07	-0.26	0.94	0.38	0.84	0.63	0.27
Net Debt	0.66	0.86	-0.08	0.6	0.57	0.61		0.58	0.31	0.7	-0.41	0.23	0.25	0.66	0.47	0.47	-0.32	0.8	0.63	-0.4	-0.23	0.77	0.17	0.47	0.52	0.19
Accounts Payable	0.78	0.85	-0.37	0.74	0.74	0.73	0.58		0.83	0.73	-0.76	0.79	-0.15	0.8	0.47	0.6	-0.33	0.75	0.93	-0.11	-0.58	0.8	-0.04	0.83	0.54	-0.2
Cash	0.78	0.76	-0.13	0.81	0.77	0.71	0.31	0.83		0.69	-0.51	0.99	-0.14	0.78	0.52	0.55	-0.3	0.63	0.73	-0.04	-0.67	0.76	0.15	0.93	0.44	-0.14
Non Current Assets Total	0.99	0.86	0.07	0.89	0.98	0.97	0.7	0.73	0.69		-0.44	0.6	0.28	0.99	0.89	0.84	-0.64	0.92	0.8	-0.11	-0.27	0.97	0.44	0.83	0.6	0.33
Non Currrent Assets Other	-0.47	-0.56	0.81	-0.31	-0.43	-0.51	-0.41	-0.76	-0.51	-0.44		-0.45	-0.08	-0.49	-0.28	-0.5	0.38	-0.59	-0.83	0.11	0.27	-0.51	0.53	-0.49	-0.44	0.59
Cash And Short Term Investments	0.69	0.7	-0.11	0.77	0.69	0.61	0.23	0.79	0.99	0.6	-0.45		-0.23	0.7	0.42	0.45	-0.19	0.53	0.66	-0.05	-0.72	0.67	0.13	0.89	0.39	-0.17
Net Receivables	0.23	0.1	0.19	0.05	0.21	0.27	0.25	-0.15	-0.14	0.28	-0.08	-0.23		0.22	0.53	0.48	-0.78	0.37	0.03	0.03	0.59	0.26	0.25	0.06	0.02	0.22
Good Will	1.0	0.88	0.04	0.92	0.99	0.97	0.66	0.8	0.78	0.99	-0.49	0.7	0.22		0.86	0.83	-0.61	0.91	0.83	-0.08	-0.36	0.98	0.41	0.9	0.58	0.25
Common Stock Total Equity	0.87	0.6	0.25	0.69	0.89	0.91	0.47	0.47	0.52	0.89	-0.28	0.42	0.53	0.86		0.94	-0.85	0.82	0.62	0.11	0.06	0.83	0.59	0.71	0.48	0.48
Common Stock Shares Outstanding	0.83	0.62	0.01	0.6	0.84	0.89	0.47	0.6	0.55	0.84	-0.5	0.45	0.48	0.83	0.94		-0.89	0.86	0.77	0.11	0.03	0.81	0.39	0.7	0.54	0.28
Short Term Investments	-0.61	-0.38	-0.09	-0.37	-0.62	-0.66	-0.32	-0.33	-0.3	-0.64	0.38	-0.19	-0.78	-0.61	-0.85	-0.89		-0.69	-0.5	-0.21	-0.36	-0.6	-0.35	-0.47	-0.29	-0.25
Non Current Liabilities Total	0.91	0.9	-0.11	0.74	0.86	0.9	0.8	0.75	0.63	0.92	-0.59	0.53	0.37	0.91	0.82	0.86	-0.69		0.86	-0.12	-0.18	0.95	0.26	0.77	0.55	0.19
Inventory	0.82	0.83	-0.44	0.67	0.79	0.83	0.63	0.93	0.73	0.8	-0.83	0.66	0.03	0.83	0.62	0.77	-0.5	0.86		-0.15	-0.41	0.84	-0.05	0.76	0.66	-0.13
Other Current Assets	-0.06	-0.3	0.09	-0.11	-0.01	-0.07	-0.4	-0.11	-0.04	-0.11	0.11	-0.05	0.03	-0.08	0.11	0.11	-0.21	-0.12	-0.15		0.45	-0.12	0.01	0.07	-0.4	0.05
Other Stockholder Equity	-0.34	-0.52	0.14	-0.54	-0.32	-0.26	-0.23	-0.58	-0.67	-0.27	0.27	-0.72	0.59	-0.36	0.06	0.03	-0.36	-0.18	-0.41	0.45		-0.35	0.01	-0.51	-0.43	0.3
Total Liab	0.98	0.94	0.0	0.91	0.95	0.94	0.77	0.8	0.76	0.97	-0.51	0.67	0.26	0.98	0.83	0.81	-0.6	0.95	0.84	-0.12	-0.35		0.37	0.89	0.6	0.23
Property Plant And Equipment Gross	0.42	0.2	0.91	0.46	0.45	0.38	0.17	-0.04	0.15	0.44	0.53	0.13	0.25	0.41	0.59	0.39	-0.35	0.26	-0.05	0.01	0.01	0.37		0.3	0.17	0.87
Total Current Assets	0.9	0.83	-0.01	0.92	0.89	0.84	0.47	0.83	0.93	0.83	-0.49	0.89	0.06	0.9	0.71	0.7	-0.47	0.77	0.76	0.07	-0.51	0.89	0.3		0.5	0.05
Short Term Debt	0.59	0.6	-0.12	0.57	0.57	0.63	0.52	0.54	0.44	0.6	-0.44	0.39	0.02	0.58	0.48	0.54	-0.29	0.55	0.66	-0.4	-0.43	0.6	0.17	0.5		0.1
Intangible Assets	0.27	0.06	0.81	0.26	0.3	0.27	0.19	-0.2	-0.14	0.33	0.59	-0.17	0.22	0.25	0.48	0.28	-0.25	0.19	-0.13	0.05	0.3	0.23	0.87	0.05	0.1

Click cells to compare fundamentals

Sanofi ADR Account Relationship Matchups

Sanofi ADR fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	112.7B	114.5B	120.2B	124.6B	126.5B	88.2B
Short Long Term Debt Total	25.9B	23.7B	22.4B	21.2B	18.4B	13.7B
Other Current Liab	298M	32M	127M	425M	13.9B	14.6B
Total Current Liabilities	20.4B	19.3B	21.3B	24.0B	24.2B	14.3B
Total Stockholder Equity	58.9B	63.0B	68.7B	73.1B	74.0B	50.2B
Property Plant And Equipment Net	11.0B	10.6B	12.0B	11.7B	11.8B	8.5B
Net Debt	16.5B	9.8B	12.3B	8.5B	9.7B	7.6B
Accounts Payable	15.3B	15.4B	17.4B	18.8B	7.3B	9.1B
Cash	9.4B	13.9B	10.1B	12.7B	8.7B	6.1B
Non Current Assets Total	83.8B	80.7B	89.6B	90.5B	95.8B	66.2B
Non Currrent Assets Other	(5.4B)	(4.0B)	(4.4B)	(5.1B)	738M	774.9M
Cash And Short Term Investments	9.4B	13.9B	10.1B	12.7B	8.7B	6.9B
Net Receivables	10.1B	1.2B	612M	374M	11.0B	6.4B
Good Will	44.5B	44.4B	48.1B	49.9B	49.4B	33.9B
Common Stock Shares Outstanding	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B
Short Term Investments	426M	900M	1.1B	664M	270M	256.5M
Liabilities And Stockholders Equity	112.7B	114.5B	120.2B	124.6B	126.5B	88.2B
Non Current Liabilities Total	33.2B	32.1B	29.9B	27.1B	27.9B	23.5B
Inventory	19.2B	18.6B	19.9B	20.9B	9.7B	11.4B
Other Current Assets	(9.8B)	83M	89M	85M	1.2B	1.0B
Other Stockholder Equity	(47.9B)	(56.4B)	(59.0B)	(64.3B)	(871M)	(827.5M)
Total Liab	53.4B	51.2B	51.2B	51.6B	52.1B	37.8B
Property Plant And Equipment Gross	11.0B	10.6B	12.0B	11.7B	27.4B	28.8B
Total Current Assets	28.9B	33.8B	30.7B	34.1B	30.7B	22.0B
Accumulated Other Comprehensive Income	52.6B	56.7B	62.2B	68.2B	4.9B	4.6B
Short Term Debt	4.8B	3.0B	3.5B	4.5B	2.3B	2.9B
Intangible Assets	16.6B	18.4B	21.4B	21.6B	73.6B	77.3B
Other Liab	12.1B	11.4B	11.0B	10.8B	12.5B	11.9B
Current Deferred Revenue	3.8B	822M	319M	264M	597M	567.2M
Retained Earnings	51.8B	60.1B	63.0B	66.7B	67.5B	64.1B
Other Assets	8.8B	11.4B	13.5B	12.9B	14.8B	9.8B
Long Term Debt	20.1B	19.7B	17.1B	14.9B	14.3B	12.7B
Property Plant Equipment	11.0B	10.6B	12.0B	11.7B	13.4B	10.5B
Deferred Long Term Liab	2.3B	6.1B	7.7B	6.2B	7.2B	4.0B
Long Term Investments	5.3B	7.1B	8.0B	9.2B	2.7B	2.5B
Short Long Term Debt	4.6B	2.8B	3.2B	4.2B	2.0B	3.2B
Net Tangible Assets	177M	6.3B	6.9B	9.5B	8.5B	4.6B

Currently Active Assets on Macroaxis

BILI	Bilibili
S	SentinelOne
BAC	Bank of America
GM	General Motors
GOOG	Alphabet Inc Class C

When determining whether Sanofi ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Sanofi ADR's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Sanofi Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Sanofi Adr Stock:

How To Invest In Sanofi

Details

Is Sanofi Stock a good investment?

Details

What is Sanofi ADR's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sanofi ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy Sanofi Stock please use our How to Invest in Sanofi ADR guide.

You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Sanofi Stock analysis

When running Sanofi ADR's price analysis, check to measure Sanofi ADR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sanofi ADR is operating at the current time. Most of Sanofi ADR's value examination focuses on studying past and present price action to predict the probability of Sanofi ADR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sanofi ADR's price. Additionally, you may evaluate how the addition of Sanofi ADR to your portfolios can decrease your overall portfolio volatility.

	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments
	Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon
	Equity Valuation Check real value of public entities based on technical and fundamental data
	USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA

Is Sanofi ADR's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sanofi ADR. If investors know Sanofi will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sanofi ADR listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.43)

Earnings Share

1.94

Revenue Per Share

18.492

Quarterly Revenue Growth

0.023

Return On Assets

0.0454

The market value of Sanofi ADR is measured differently than its book value, which is the value of Sanofi that is recorded on the company's balance sheet. Investors also form their own opinion of Sanofi ADR's value that differs from its market value or its book value, called intrinsic value, which is Sanofi ADR's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sanofi ADR's market value can be influenced by many factors that don't directly affect Sanofi ADR's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Sanofi ADR's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sanofi ADR is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sanofi ADR's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Sanofi Long Term Debt Total vs Net Working Capital Analysis

Long Term Debt Total vs Net Working Capital

Long Term Debt Total vs Net Working Capital Correlation Analysis

Correlation Coefficient

Long Term Debt Total

Net Working Capital

Sanofi ADR fundamental ratios Correlations

Sanofi ADR Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Sanofi ADR fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Sanofi Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Good Will	+ 1.0	Total Assets
Total Stockholder Equity	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Total Assets
Good Will	+ 0.99	Total Stockholder Equity
Cash And Short Term Investments	+ 0.99	Cash
Good Will	+ 0.99	Non Current Assets Total

Short Term Investments	- 0.89	Common Stock Shares Outstanding
Short Term Investments	- 0.85	Common Stock Total Equity
Inventory	- 0.83	Non Currrent Assets Other
Short Term Investments	- 0.78	Net Receivables
Non Currrent Assets Other	- 0.76	Accounts Payable
Other Stockholder Equity	- 0.72	Cash And Short Term Investments